# US 2024/0173425 A1 · Human cd33 antibodies and glucocorticoid conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173425 A1
- Document ID: US20240173425A1
- Status: Published application
- Kind: A1
- Application number: 18/338,468
- Filed: 2023-06-21
- Published: 2024-05-30
- Earliest claimed: 2022-06-22
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Forest Hoyt Andrews; Joshua Ryan Clayton; Ross Edward Fellows; Bo Ma; Ying Tang; Jacqueline Mary Wurst; Pia Pauliina Yachi; Chiao-Wen Yang
- Web page: https://patentgrep.com/patent/US20240173425A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides human CD33 antibodies and antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of myeloid cell associated diseases.

## Claims

### Claim 1

An antibody that binds human CD33, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
i. the HCDR1 comprises SEQ ID NO: 1,
the HCDR2 comprises SEQ ID NO: 2,
the HCDR3 comprises SEQ ID NO: 3,
the LCDR1 comprises SEQ ID NO: 4,
the LCDR2 comprises SEQ ID NO: 5, and
the LCDR3 comprises SEQ ID NO: 6;
ii. the HCDR1 comprises SEQ ID NO: 1,
the HCDR2 comprises SEQ ID NO: 2,
the HCDR3 comprises SEQ ID NO: 3,
the LCDR1 comprises SEQ ID NO: 13,
the LCDR2 comprises SEQ ID NO: 5, and
the LCDR3 comprises SEQ ID NO: 6; or
iii. the HCDR1 comprises SEQ ID NO: 1,
the HCDR2 comprises SEQ ID NO: 2,
the HCDR3 comprises SEQ ID NO: 17,
the LCDR1 comprises SEQ ID NO: 18,
the LCDR2 comprises SEQ ID NO: 5, and
the LCDR3 comprises SEQ ID NO: 6.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein,
i. the VH comprises SEQ ID NO: 7 and the VL comprises SEQ ID NO: 8;
ii. the VH comprises SEQ ID NO: 7 and the VL comprises SEQ ID NO: 14; or
iii. the VH comprises SEQ ID NO: 19 and the VL comprises SEQ ID NO: 20.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain (HC) and a light chain (LC), wherein
i. the HC comprises SEQ ID NO: 9 and the LC comprises SEQ ID NO: 10;
ii. the HC comprises SEQ ID NO: 9 and the LC comprises SEQ ID NO: 15;
or
iii. the HC comprises SEQ ID NO: 21 and the LC comprises SEQ ID NO: 22.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain (HC) and a light chain (LC), wherein the HC is human IgG1 isotype.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody is an internalizing antibody.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is a non-depleting antibody.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody is a non-degrading antibody.

### Claim 8

A nucleic acid comprising a sequence encoding SEQ ID NO: 9, 10, 15, 21, or 22.

### Claim 9 (depends on 8)

A vector comprising the nucleic acid of claim 8.

### Claim 10 (depends on 9)

The vector of claim 9, wherein,
i. the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 10;
ii. the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 15; or
iii. the vector comprises a first nucleic acid sequence encoding SEQ ID NO: and a second nucleic acid sequence encoding SEQ ID NO: 22.

### Claim 11

A composition comprising:
i. a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 21 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 22;
ii. first vector comprising a nucleic acid sequence encoding SEQ ID NO: 9 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 10; or
iii. a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 9 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 15.

### Claim 12 (depends on 9)

A cell comprising the vector of claim 9.

### Claim 13 (depends on 10)

A cell comprising the vector of claim 10.

### Claim 14 (depends on 12)

The cell of claim 12, wherein the cell is a mammalian cell.

### Claim 15 (depends on 13)

The cell of claim 13, wherein the cell is a mammalian cell.

### Claim 16 (depends on 15)

A process of producing an antibody comprising culturing the cell of claim 15, under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.

### Claim 17 (depends on 16)

An antibody produced by the process of claim 16.

### Claim 18 (depends on 1)

A conjugate comprising an antibody of claim 1, wherein the antibody is conjugated to a therapeutic agent.

### Claim 19 (depends on 18)

The conjugate of claim 18, wherein the therapeutic agent comprises a cytotoxic agent, siRNA, saRNA, peptide, oligonucleotide, small molecule, nanoparticle, lipid nanoparticle, exosome, antibody or antigen binding fragment thereof, or a combination thereof.

### Claim 20

A conjugate of the Formula:
wherein Ab is an antibody that binds human CD33,
wherein
and n is 1-5.

### Claim 21 (depends on 20)

The conjugate of claim 20 wherein

### Claim 22 (depends on 20)

The conjugate of claim 20 wherein

### Claim 23 (depends on 20)

The conjugate of claim 20 wherein

### Claim 24 (depends on 20)

The conjugate of claim 20 wherein

### Claim 25 (depends on 20)

The conjugate of claim 20 wherein

### Claim 26 (depends on 20)

The conjugate of claim 20 wherein

### Claim 27 (depends on 20)

The conjugate of claim 20 wherein

### Claim 28 (depends on 20)

The conjugate of claim 20 wherein

### Claim 29 (depends on 20)

The conjugate of claim 20, wherein the Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
the HCDR1 comprises SEQ ID NO: 1,
the HCDR2 comprises SEQ ID NO: 2,
the HCDR3 comprises SEQ ID NO: 3,
the LCDR1 comprises SEQ ID NO: 4,
the LCDR2 comprises SEQ ID NO: 5, and
the LCDR3 comprises SEQ ID NO: 6.

### Claim 30 (depends on 29)

The conjugate of claim 29, wherein the VH comprises SEQ ID NO: 7 and the VL comprises SEQ ID NO: 8.

### Claim 31 (depends on 29)

The conjugate of claim 29, wherein the Ab comprises a heavy chain (HC) comprising SEQ ID NO: 9 and a light chain (LC) comprising SEQ ID NO: 10.

### Claim 32 (depends on 20)

The conjugate of claim 20, wherein the Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
the HCDR1 comprises SEQ ID NO: 1;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 3;
the LCDR1 comprises SEQ ID NO: 13;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6.

### Claim 33 (depends on 32)

The conjugate of claim 32, wherein the VH comprises SEQ ID NO: 7 and the VL comprises SEQ ID NO: 14.

### Claim 34 (depends on 32)

The conjugate of claim 32, wherein the Ab comprises a heavy chain (HC) comprising SEQ ID NO: 9 and a light chain (LC) comprising SEQ ID NO: 15.

### Claim 35 (depends on 20)

The conjugate of claim 20, wherein the Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
the HCDR1 comprises SEQ ID NO: 1;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 17;
the LCDR1 comprises SEQ ID NO: 18;
the LCDR2 comprises SEQ ID NO: 5, and the LCDR3 comprises SEQ ID NO: 6.

### Claim 36 (depends on 35)

The conjugate of claim 35, wherein the VH comprises SEQ ID NO: 19 and the VL comprises SEQ ID NO: 20.

### Claim 37 (depends on 35)

The conjugate of claim 35, wherein the Ab comprises a heavy chain (HC) comprising SEQ ID NO: 21 and a light chain (LC) comprising SEQ ID NO: 22.

### Claim 38 (depends on 20)

The conjugate of claim 20, wherein the Ab comprises a heavy chain and a light chain, wherein the heavy chain comprises:
a cysteine at amino acid residue 124 (EU numbering);
a cysteine at amino acid residue 378 (EU numbering); or
a cysteine at amino acid residue 124 (EU numbering) and a cysteine at amino acid residue 378 (EU numbering).

### Claim 39 (depends on 20)

The conjugate of claim 20, wherein the Ab comprises a heavy chain (HC) and a light chain (LC), wherein the HC is human IgG1 isotype.

### Claim 40 (depends on 20)

The conjugate of claim 20, wherein n is 2-5.

### Claim 41 (depends on 20)

The conjugate of claim 20, wherein n is 3-4.

### Claim 42 (depends on 20)

The conjugate of claim 20, wherein n is about 2, 3, or 4.

### Claim 43 (depends on 20)

A pharmaceutical composition comprising the conjugate of claim 20 and one or more pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 44 (depends on 20)

A method of treating a myeloid cell associated disease in a subject in need thereof, comprising administering to the subject an effective amount of the conjugate of claim 20.

### Claim 45 (depends on 43)

A method of treating a myeloid cell associated disease in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 43.

### Claim 46 (depends on 44)

The method of claim 44, wherein the myeloid cell associated disease is an immune disease, neurodegenerative disease, or cancer.

### Claim 47 (depends on 46)

The method of claim 46, wherein the immune disease is rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, giant cell arteritis, polymyalgia rheumatica, psoriatic arthritis, atopic dermatitis, psoriasis, ulcerative colitis, Crohn's disease, dermatomyositis, Juvenile idiopathic arthritis, multiple sclerosis, Sjogren's syndrome, macrophage activation syndrome, or fibrotic diseases.

### Claim 48 (depends on 47)

The method of claim 47, wherein the immune disease is rheumatoid arthritis.

### Claim 49

A method of producing a conjugate, comprising the steps of:
(a) reducing anti-human CD33 antibody with a reducing agent to produce a reduced anti-human CD33 antibody, wherein the anti-human CD33 antibody comprises one or more engineered cysteine residues;
(b) oxidizing the reduced anti-human CD33 antibody with an oxidizing agent to produce an oxidized anti-human CD33 antibody; and
(c) contacting the oxidized anti-human CD33 antibody with the compound of the formula
to produce the conjugate.

### Claim 50 (depends on 49)

The method of claim 49, wherein the reducing agent is dithiothreitol and the oxidizing agent is dehydroascorbic acid.
